HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Higashimoto, Y. Articles by Itoh, H. Search for Related Content PubMed PubMed Citation Articles by Higashimoto, Y. Articles by Itoh, H.

Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients

Dept of Internal Medicine, Wakayama Medical University Kihoku Hospital, Ito-gun, Wakayama Prefecture, Japan

CORRESPONDENCE: Y. Higashimoto, Wakayama Medical University Kihoku Hospital, 219 Myoji, Katsuragi-cho, Ito-gun, Wakayama Prefecture 649-7113, Japan. Fax: 81 736222579. E-mail: yhigashi@wakayama-med.ac.jp

Keywords: Bronchial asthma, chronic obstructive pulmonary disease, exacerbation, metalloproteinases, serum markers, tissue inhibitors of matrix metalloproteinases

Received: August 7, 2004
Accepted December 13, 2004

Matrix metalloproteinase (MMP)-9 and tissue inhibitors of metalloproteinase (TIMP)-1 concentrations are increased in the sputum of asthma and chronic bronchitis patients, and are thought to be related to airflow obstruction. However, serum concentrations of these enzymes have not been clearly evaluated in patients with chronic obstructive pulmonary disease (COPD). The aim of this study was to examine the serum concentrations of these enzymes in COPD and asthmatic patients in order to determine their relationship with airway obstruction.

Serum samples were obtained from 72 patients with COPD: 66 control subjects and 26 patients with asthma. Smoking histories of control subjects were matched with those of COPD patients. Serum concentrations of TIMP-1 and MMP-9 were determined by ELISA.

The circulating TIMP-1 concentration was significantly higher in stable COPD patients than in control and asthmatic subjects, and was significantly negatively correlated with forced expiratory volume in one second/forced vital capacity in COPD patients. The molar ratio between MMP-9 and TIMP-1 was significantly lower in COPD patients than in control subjects. In patients with COPD, the serum TIMP-1 concentration was significantly increased during disease exacerbation.

In conclusion, the current findings suggest that serum tissue inhibitors of metalloproteinase-1 concentration can be used as a serum marker of airway obstruction and exacerbation in chronic obstructive pulmonary disease patients.

This article has been cited by other articles:

				V. Pinto-Plata, J. Toso, K. Lee, D. Park, J. Bilello, H. Mullerova, M. M De Souza, R. Vessey, and B. Celli Profiling serum biomarkers in patients with COPD: associations with clinical parameters Thorax, July 1, 2007; 62(7): 595 - 601. [Abstract] [Full Text] [PDF]

				C. Bergeron, M. K. Tulic, and Q. Hamid Tools used to measure airway remodelling in research Eur. Respir. J., March 1, 2007; 29(3): 596 - 604. [Abstract] [Full Text] [PDF]

				Y. Higashimoto From the authors Eur. Respir. J., August 1, 2005; 26(2): 365 - 366. [Full Text] [PDF]

				M. John and K. Jung Pre-analytical conditions for the assessment of circulating MMP-9 and TIMP-1: consideration of pitfalls Eur. Respir. J., August 1, 2005; 26(2): 364 - 365. [Full Text] [PDF]